Literature DB >> 14617632

Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes.

Adam J Krieg1, Sacha A Krieg, Bonnie S Ahn, David J Shapiro.   

Abstract

To examine the role of the estrogen response element (ERE) sequence in binding of liganded estrogen receptor (ER) to promoters, we analyzed in vivo interaction of liganded ER with the imperfect ERE in the pS2 gene and the composite estrogen-responsive unit (ERU) in the proteinase inhibitor 9 (PI-9) gene. In transient transfections of ER-positive HepG2-ER7 cells, PI-9 was strongly induced by estrogen, moxestrol (MOX), and 4-hydroxytamoxifen (OHT). PI-9 was not induced by raloxifene or ICI 182,780. Quantitative reverse transcriptase-PCR showed that moxestrol strongly induced cellular PI-9 and pS2 mRNAs, whereas OHT moderately induced PI-9 mRNA and weakly induced pS2 mRNA. Chromatin immunoprecipitation experiments demonstrated strong and similar association of 17beta-estradiol-hERalpha and MOX-hERalpha with the PI-9 ERU and with the pS2 ERE. Binding of MOX-hERalpha to the PI-9 ERU and the pS2 ERE was rapid and continuous. Although MOX-hERalpha bound strongly to the PI-9 ERU and less well to the pS2 ERE in chromatin immunoprecipitation, gel shift assays showed that estrogen-hERalpha binds with higher affinity to the deproteinized pS2 ERE than to the PI-9 ERU. Across a broad range of OHT concentrations, OHT-hERalpha associated strongly with the pS2 ERE and weakly with the PI-9 ERU. ICI-hERalpha bound poorly to the PI-9 ERU and effectively to the pS2 ERE. Raloxifene-hERalpha and MOX-hERalpha exhibited similar binding to the PI-9 ERU and the pS2 ERE. These studies demonstrate that ER ligand and ERE sequence work together to regulate in vivo binding of ER to estrogen-responsive promoters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617632     DOI: 10.1074/jbc.M307076200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  Small molecule inhibitors as probes for estrogen and androgen receptor action.

Authors:  David J Shapiro; Chengjian Mao; Milu T Cherian
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

2.  Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzo-p-dioxin-responsive promoters.

Authors:  Jason Matthews; Björn Wihlén; Jane Thomsen; Jan-Ake Gustafsson
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.

Authors:  Nicole M Kretzer; Milu T Cherian; Chengjian Mao; Irene O Aninye; Philip D Reynolds; Rachel Schiff; Paul J Hergenrother; Steven K Nordeen; Elizabeth M Wilson; David J Shapiro
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

4.  BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.

Authors:  Shyam Nathan; Yongxian Ma; York A Tomita; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Breast Cancer Res Treat       Date:  2017-08-14       Impact factor: 4.872

5.  Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.

Authors:  Liqun Yu; Lawrence Wang; Chengjian Mao; Darjan Duraki; Ji Eun Kim; Rui Huang; William G Helferich; Erik R Nelson; Ben Ho Park; David J Shapiro
Journal:  Cancer Lett       Date:  2018-11-09       Impact factor: 8.679

Review 6.  The immune system and inflammation in breast cancer.

Authors:  Xinguo Jiang; David J Shapiro
Journal:  Mol Cell Endocrinol       Date:  2013-06-19       Impact factor: 4.102

7.  Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells.

Authors:  Xinguo Jiang; Nicole M Patterson; Yan Ling; Jianwei Xie; William G Helferich; David J Shapiro
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

8.  Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity.

Authors:  Thomas D Cunningham; Xinguo Jiang; David J Shapiro
Journal:  Cell Immunol       Date:  2007-05-08       Impact factor: 4.868

9.  Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection.

Authors:  C F Classen; P I Bird; K-M Debatin
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

10.  A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.

Authors:  Chengjian Mao; Nicole M Patterson; Milu T Cherian; Irene O Aninye; Chen Zhang; Jamie Bonéy Montoya; Jingwei Cheng; Karson S Putt; Paul J Hergenrother; Elizabeth M Wilson; Ann M Nardulli; Steven K Nordeen; David J Shapiro
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.